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Background: There is no standardized procedure or consensus to which tests should be performed to judge
compatibility/incompatibility of intravenous drugs. The purpose of this study was to establish and evaluate a test
program of methods suitable for detection of physical incompatibility in Y-site administration of total parenteral
nutrition (TPN) and drugs.
Methods: Eight frequently used methods (dynamic light scattering, laser diffraction, light obscuration, turbidimetry,
zeta potential, light microscopy, pH-measurements and visual examination using Tyndall beams), were scrutinized
to elucidate strengths and weaknesses for compatibility testing. The responses of the methods were tested with
samples containing precipitation of calcium phosphate and with heat destabilized TPN emulsions. A selection of
drugs (acyclovir, ampicillin, ondansetron and paracetamol) was mixed with 3-in-1 TPN admixtures (Olimel® N5E,
Kabiven® and SmofKabiven®) to assess compatibility (i.e. potential precipitates and emulsion stability). The obtained
compatibility data was interpreted according to theory and compared to existing compatibility literature to further
check the validity of the methods.
Results: Light obscuration together with turbidimetry, visual inspection and pH-measurements were able to
capture signs of precipitations. For the analysis of emulsion stability, light obscuration and estimation of percent
droplets above 5 μm (PFAT5) seemed to be the most sensitive method; however laser diffraction and monitoring
changes in pH might be a useful support. Samples should always be compared to unmixed controls to reveal
changes induced by the mixing. General acceptance criteria are difficult to define, although some limits are
suggested based on current experience. The experimental compatibility data was supported by scattered reports
in literature, further confirming the suitability of the test program. However, conflicting data are common, which
complicates the comparison to existing literature.
Conclusions: Testing of these complex blends should be based on a combination of several methods and
accompanied by theoretical considerations.
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Critically ill hospitalized patients are often in need of
many intravenous drugs, and a frequent problem is the
lack of sufficient number of access sites or available lumen
in multi-lumen catheters, to administer each product
separately [1]. If a patient receives a continuous infusion
of total parenteral nutrition (TPN), the infusion should be
stopped and the line flushed before administration of
other drugs in the same line [2, 3]. However, frequent
stops may lead to under-nutrition, and the repeated flush-
ing may be problematic with regard to the patient’s fluid
balance [4]. In this situation it might be beneficial to co-
administer drugs and TPN through a Y-site connector.
Unfortunately, there is still a lack of documented ex-
perimental compatibility data [5, 6], and extrapolation
of results can be difficult and risky [2, 3].
TPN admixtures as such are complex with a lot of
possible physicochemical interactions [7–10]. Mixing TPN
with drugs further complicates the picture [7, 10–14],
potentially leading to chemical and/or physical incompati-
bility. Chemical degradation of ingredients (chemical
incompatibility) [5, 15] is less relevant for Y-site admin-
istration because of the short contact time [5, 12, 14].
The focus of this paper is therefore on physical incom-
patibility that is precipitation of particles or growth of
droplets leading to destabilization of the lipid emulsion
[3, 11–14]. Both precipitates and large oil droplets can
potentially be dangerous upon infusion. Cases of pul-
monary emboli with fatale outcome have been reported
after the administration of TPN containing calcium
phosphate precipitates [16]. Also, deaths of neonatal
patients caused by an incompatibility between ceftriaxone
and calcium-containing products (ceftriaxone-calcium
precipitate), have occurred [17]. The effects from injecting
large (>5 μm) oil droplets are less clear, but animal studies
have indicated that enlarged oil droplets can harm the
lungs and liver [18, 19]. Furthermore, critically ill neonates
receiving fat emulsions containing a high proportion of
“large diameter tail” oil droplets, showed higher frequency
of hypertriglyceridemia and poorer plasma clearance of
lipids, compared to those receiving products with fewer
large droplets [20]. There are also reports of emboli-like
effects as a complication of intravenous fat emulsion
administration [21, 22] although it is believed that the
body can handle soft and flexible particles like oil droplets
better than harder particles [23].
Since incompatibility might have serious consequences,
compatibility data has to be based on solid documentation.
However, there seems to be no consensus in literature to
which tests should be performed to check incompatibility
or what are the assessment criteria. Different studies apply
different methods and the results are interpreted relatively
to their test set. Some studies are based on only visual
observations [12, 24], others include a few instrumentalmethods in addition [25–27], whereas some use more
extensive set-ups with a combination of several methods
[13, 28]. Assessment of possible precipitates are typically
performed by one or more of the following approaches:
visual examination with Tyndall light [11, 12, 24, 29] or
other visual examination methods [13, 27, 30, 31], turbidi-
metric measurements [26, 29], colorimetric measurement
[13], light obscuration (LO) [13, 31], dynamic light scatter-
ing (DLS) [27], microscopy [32] and pH-measurements
[30–32]. Various methods have also been used to investi-
gate parenteral emulsion stability: visual observation with
[12] or without a centrifugation step [13, 25, 28, 32–35],
determination of zeta potential [25, 28, 34, 36–38], meas-
urement of dynamic surface tension [37], measurement of
peroxide levels [28], pH-measurements [13, 25, 28, 33–35]
and different droplet size measurement techniques. The
latter techniques are e.g. microscopy [13, 28, 36, 37], DLS
[13, 28, 33, 35–38], laser diffraction (LD) [25, 35, 36],
flow cytometry [32], coulter counter [34, 36] and LO
[13, 28, 33]. The list is not complete, but illustrates the
diversity in methodology.
Also the acceptance criteria vary or may not be defined
clearly. E.g. for electronically counting of particles, aiming
at elucidating precipitates, some use the limits in the
Pharmacopoeia for large volume parenterals; not more
than 25 particles/ml ≥ 10 μm and 3 particles/ml ≥ 25 μm
[13, 39]. Others also include smaller particles [31]. For tur-
bidimetric measurements a change in turbidity by 0.5
NTU was defined as incompatibility by Trissel and Bready
[29], and applied as specification in some compatibility
studies [11, 26]. Also when it comes to the lipid emulsion
stability, different criteria have been suggested, e.g. the
many approaches to interpret stability based on micros-
copy data [13, 28, 36, 37, 40]. After inclusion of the droplet
size requirements in the USP [41] (formally adopted in
2007 [42]), there are some official guidelines, even though
equivalent requirements have not been adapted by the
European Pharmacopeia. The USP standards states that
the mean droplet diameter (MDD) in lipid injectable
emulsions should be < 500 nm, measured by DLS or LD,
and that the volume-weighted (V.W.) percentage of fat
with droplet diameter above 5 μm (PFAT5) measured by
LO, should be ≤ 0.05 % [41]. Although the USP limits are
intended for “pure” lipid emulsions (10-30 % w/v emul-
sion) [41, 43], these limits have also been applied when
the lipid emulsion is part of complex mixtures such as
TPN [28, 44–46]. Extemporaneously prepared TPN ad-
mixtures may be less stable, and the limit of 0.05 % might
be too strict; hence the use of PFAT5 < 0.40 % (one log
higher) has been proposed as the acceptance criteria
[47], although studies indicate that it is possible to for-
mulate extempore TPN preparations that also fulfills
the PFAT5 limit of the USP [45–47]. Driscoll and co-
workers introduced PFAT5 > 0.40 % as a critical value
Table 1 Overview of investigated 3-in-1 TPN admixtures and
additives
Product type Brand name Manufacturer Lot No.
3-in-1 TPN admixture Olimel® N5E Baxter 11B10N10
11C27N10
10J11N40
12J03N12
13C21N10
3-in-1 TPN admixture Kabiven® Fresenius Kabi 10BG8759
10GD1825
10GH5541
3-in-1 TPN admixture SmofKabiven® Fresenius Kabi 10GH6092
10GM1499
10HA2174
Trace elements Tracel® Fresenius Kabi 12ECB12
12EFR02
12FCB12
12GHB16
12GLB03
Vitamins water soluble Soluvit® Fresenius Kabi 10EE4869
10EF6004
10GD1632
10GI7229
10GM1588
Vitamins lipid-soluble Vitalipid® Adult Fresenius Kabi 10 EB2248
10EL1064
10GD1922
10GK7978
10GK7972
10GF4227
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that above this critical limit phase separation is likely to
occur [33]. A PFAT5 limit of < 0.40 % has been applied
as acceptance criteria in a compatibility study [13].
Attention has been drawn to the discrepancies be-
tween compatibility studies, and more standardization in
conducting such studies and reporting from these are re-
quested [5]. This work aimed to develop and evaluate a
test program suitable to detect physical incompatibility
of drugs and TPN in simulated Y-site administration.
Methods frequently applied in the literature were scruti-
nized, and a selection of methods was tested in order to
elucidate their strengths and weaknesses for compatibility
testing purpose. The methods should be able to detect
both signs of precipitation and emulsion destabilization.
Incompatibility was defined as indications of an increase
in size and/or number of particles, and/or an increase in
lipid droplet size, both as compared to original, not-mixed
samples of drug and TPN. To map the responses in the
methods, TPN admixtures were subjected to stressful
conditions (pH and temperature) to force physical incom-
patibility, i.e. precipitation and emulsion destabilization.
To further evaluate the test program, three 3-in-1 TPN
admixtures were tested with a selection of drugs. These
drugs had previously been reported as compatible and
some incompatible with TPN in the literature, or the exist-
ing data was conflicting. Based on the findings in the
current study, a final selection of methods was chosen to
constitute a test program. Suggestions for acceptance
criteria were also formulated.
Materials and methods
Materials
Overview of the investigated 3-in-1 TPN admixtures,
additives, drugs, dilution media and concentrations are
listed in Tables 1 and 2. Four different paracetamol
products were tested, and their composition is presented in
Table 3. Formazin 4000 NTU, used to prepare formazin
standards, was from Orion Application Solution (Thermo
Scientific, Waltham, USA). Sodium hydroxide was from
Sigma Aldrich (Seelze, Germany) and water was of Milli-Q
quality (Millipore, Molsheim, France). Polystyrene stan-
dards (EZY-CALTM/DUKE STANDARDSTM Microsphere
Size Standards, NIST Traceable Mean Diameter) were
from Thermo Scientific (Fremont, USA).
Experimental design
Three commercially available 3-in-1 TPN products for
central administration were studied. Drugs were chosen
to demonstrate different types and degrees of incompati-
bilities with TPN. Pediatric patients is a vulnerable group,
therefore concentrations of the drugs were selected to be
clinically relevant for children from age of 2. The drug
concentrations were selected in dialog with clinicians.Glucose 50 mg/ml was preferred as dilution media as this
is recommended in children; sodium chloride 9 mg/ml
was used when drugs were unstable in and/or incom-
patible with glucose according to the respective SmPC
(Table 2). Tracel® and Vitalipid® Adult were chosen as
additions of trace elements and fat soluble vitamins, instead
of Peditrace® and Vitalipid® Infant. The latter products are
used in the smallest children, but since Tracel® contains
more types of trace elements and in higher concentration,
adding Tracel® would represent the worst-case scenario.
Vitalipid® Adult contains more of vitamin A and E, but less
of K and D. Both vitamin products could have been used,
but Vitalipid® Adult were chosen to “match” Tracel®, since
both are used in the older children.
Aliquots of TPN were mixed with drug in sterile
50 ml polypropylene centrifuge tubes (VWR, Radnor,
USA/Corning Incorporated, New York, USA) in three
parallels of the mixing ratio 1 + 1. The order of mixing
Table 2 Overview of investigated drugs and concentrations
Drug Manufacturer Lot No. Dilution
media
Concentration
after dilution
(mg/ml)
Acyclovir
sodium
Hospira X171213AA
X101213AB
A101193AA
A101213AA
Y131213AB
Glucose
50 mg/ml
5 mg/ml
Ampicillin
sodium
Bristol-Myers
Squibb
2A00936
3E02641
0059774
3J01732
3L01792
3F02259
1E00687
1J00117
1C00905
0G56375
1A00661
0L60962
0J63206
3C02634
NaCl
9 mg/ml
50 mg/ml
APP
Pharmaceuticals
1K10AK
SAGENT
Pharmaceuticals
P3667
Ondansetron
hydrochloride
Copyfarm 9278
18DI32602
18D350301
Glucose
50 mg/ml
0.2 mg/ml
Fresenius Kabi 18F321601
18G207503
18G157402
18F321601
18E272402
18E183801
19E18380
Accord
Healthcare
N08669
M13242
Paracetamol Bristol-Myers
Squibb
0M44297
1E63971
Undiluted 10 mg/ml
Fresenius Kabi 14GC20
14GF36
16FD0093
16EM0155
B. Braun 13486404
13487404
14382407
Actavis 14EE30
14EH47
16EM0155
Table 3 Composition of paracetamol formulations tested
(Source: SmPC of the respective paracetamol products)
Pharmaceutical excipient Bristol-Myers
Squibba/Actavisa
Fresenius
Kabib
B. Braunc
Cysteine hydrochloride
monohydrate
+ +
Disodium phosphate
dihydrate
+
Hydrochloric acid +
Mannitol + + +
Sodium hydroxide +
Water for injections + + +
Hydroxyethyl starch +
Sodium acetate trihydrate +
Sodium citrate dihydrate +
Acetic acid, glacial +
pH 5.5 5.0-7.0 4.5-5.5
a: tested with Olimel® N5E except for PFAT and laser diffraction measurements
b: tested with Kabiven® except for PFAT and laser diffraction measurements
c: tested with SmofKabiven®, all methods + with Olimel® N5E and Kabiven®
with regard to PFAT and laser diffraction measurements
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laminar airflow safety cabinet. Under the assumption
that most incompatibilities worsen with increasing time,
the samples were analyzed at two time points; immedi-
ately after mixing, which due to practical handling was
within one hour and again four hours after mixing.
However, the chance that e.g. a momentary precipitation
would re-dissolve before detection cannot be excluded.
Such a precipitate was regarded as less dangerous ifinfused, since it is likely to dissolve fast upon dilution in
the circulation. Appropriate controls (pure TPN and pure
drug solution) were used for comparison. TPN samples
were also subjected to emulsion destabilization by heat
(45 °C for 2 and 4 days) and addition of 0.1 M NaOH to
induce alkaline pH, forcing precipitation of calcium phos-
phate. The analysis was performed under ambient labora-
tory conditions. The prepared TPN bags were stored in
the fridge (4–8 °C) between sampling, and used before
end of the maximal recommended storage time stated by
the manufacturers (generally up to six days in fridge).
The milk-white appearance of TPN prohibits the direct
assessment of potential precipitation. Therefore, sample
preparation and the subsequent analysis were divided into
two parts: assessment of potential precipitate (fat free
TPN) and analysis of emulsion stability (all constituents of
TPN present). The details of the methods are described
below.
Assessment of potential precipitate
Sample preparation
Two sample preparation approaches were evaluated: I)
All three compartments of the 3-in-1 TPN-bag were
blended, trace elements and vitamins added, and then
mixed with drug. The mixtures were subjected to centri-
fugation (15 000 × g, 20 min, 23 °C) and the lipid layer
on top was gently removed using a glass-pipette connected
to a vacuum line [12]. II) The amino acid compartment
and the glucose compartment were mixed, and Milli-Q-
water was added to replace the lipid emulsion [48]. Trace
elements were added, but vitamins were omitted to avoid
disturbances from strong color, especially with regard to
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referred to as TPNaq to emphasize the lipid-free alternative
[48]. Both TPNaq and drugs were filtered 0.22 μm before
mixing.
Visual examination using Tyndall light
Visual examination was carried out to identify Tyndall
effect and light scattering from potential precipitated
particles. Samples were mixed in sterile, Milli-Q-water
rinsed, 100 × 24 × 0.9-1.0 mm flat-bottom glass tubes
(Scherf Präzision Europa GmbH, Meiningen, Germany)
instead of the centrifuge tubes. Three different light
sources were applied: I) a 75 watt halogen light bulb in a
desk lamp, covered with an aluminum plate with a 1.5 cm
diameter hole to focus the light, II) a red pocket laser
pointer (630–650 nm, max output <1 mW), and III) a
fiber optic light source (Schott KL 1600 LED, Mainz,
Germany). The samples were studied against a black back-
ground in a dark room as described earlier [48].
Light obscuration analysis
Sub-visual particles were counted using LO (Accusizer
780 Optical Particle Sizer, Nicomp PSS, Santa Barbara,
USA). The performance of the instrument was verified
with polystyrene microsphere standards. The principle
of LO is the momentary blockage (large particles) or
scattering (small particles) of light when particles pass
through a sensing zone illuminated by a laser beam. This
creates a pulse that translates to a specific particle size
when compared to an established calibration curve [49].
Given that the concentration is sufficiently dilute, this is
an optical single particle counting technique where the
number and size of individual particles are estimated
one at a time [49]. Too high concentrations can lead to
multiple particles (clusters) being sized and counted as
one particle. The sensor was LE-400-05 in summation
mode, measuring particles from 0.5 to 400 μm. The
background count of the centrifugation tubes was below
100 particles/ml ≥ 0.5 μm.
15 ml of sample was measured undiluted to avoid dissol-
ution of precipitate. The total particle count/ml ≥ 0.5 μm
and the amount of particles ≥ 5, 10 and 25 μm per ml [39]
were determined. In addition the particle content of TPNaq
with increasing amount of 0.1 M NaOH was measured.
Also, a sample of known incompatibility (acyclovir: TPNaq
1 + 1) was measured every 30 min after mixing up to 4 h.
Turbidity measurements
Two methods were employed to evaluate turbidity, a ra-
tio turbidimeter (2100Qis Turbidimeter, Hach Lange
GmbH, Düsseldorf, Germany) measuring in formazin
nephelometry units (FNU) and an UV–VIS spectropho-
tometer (Agilant 8453 UV-visible Spectroscopy system,
Agilent Technologies, Santa Clara, USA) measuring the% transmittance in 1 cm quartz cuvettes at 550 nm [50].
Relative transmittance was calculated from T/T0, where
T is the % transmittance in samples and T0 is the %
transmittance in pure TPNaq or Milli-Q-water respect-
ively [50]. Ratio turbidimetry measures the scattering of
incident light at different angles, formed due to light
interacting with particles present in the samples [51]. In
an UV–VIS spectrophotometer the incident light is at-
tenuated by particles present, and the remaining light
reaching the detector at 180° relative to the incident
light path is measured [51]. Both instruments were vali-
dated with formazin standards of 3, 6, 18 and 30 NTU
as described in Ph. Eur. [52].
The turbidity (FNU) of TPNaq with increasing alkalinity
(i.e. calcium phosphate precipitation) and TPNaq mixed
with acyclovir (same as for LO: every 30 min after mixing
up to 4 h), were measured. To further check the correl-
ation between the methods, low turbidity samples (<1
FNU) were measured with both instruments (ampicillin
alone, ampicillin with TPNaq, paracetamol alone, para-
cetamol with TPNaq, and ondansetron with TPNaq).
pH measurements and theoretical consideration
The pH of samples was measured with a pH meter
(Metrohm 744 pH Meter, Metrohm AG, Herisau,
Switzerland) calibrated with buffers of pH 4.00 and
7.00. For samples involving alkali drugs calibration
buffers of pH 10.00 was included in the calibration. A
theoretical evaluation of solubility and compatibility
was also performed.
Emulsion stability analysis
Sample preparation
All three chambers of the TPN-bags were mixed and vita-
mins and trace elements were added. Drugs, but not TPN,
were filtered 0.22 μm. In addition to drug: TPN-samples,
heat treated TPN as described above, were analyzed.
Dynamic light scattering
The intensity weighted (I.W.) MDD and polydispersity
index (PI) were estimated using DLS (Submicron Particle
Sizer Modell 370, Nicomp PSS, Santa Barbara, USA). The
principle of DLS is the measurement of temporal fluctua-
tions in scattered light caused by the Brownian motion of
small particles in dispersion. From this the hydrodynamic
diameter of the particle distribution can be deduced.
DLS measures particles from nanometers to a few microns
[49]. Prior to measurements the performance of the in-
strument was verified with polystyrene microspheres.
The samples were diluted in Milli-Q-Water in disposable
borosilicate glass culture tubes of 6x50 mm (Kimble
Chase, Rockwood, USA) to an intensity of 250–350 KHz
and measured.
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The V.W. MDD and V.W. percent of particles below
500 nm and 1 μm, and above 5 and 10 μm, were estimated
using LD (Mastersizer 2000 and Hydro 2000G sample dis-
persion unit) (Malvern Instruments, Worcestershire, UK).
LD measures the angular light scattering pattern of parti-
cles in dispersion. Light is scattered differently relative to
particle size; small angles for large particles and large an-
gles for small particles. Based on the scattered pattern the
particle size distribution can be estimated, and typically re-
ported on a volume basis. The measuring range is broad,
from nanometers to millimeters [49]. Like DLS, LD is an
ensemble technique, i.e. the collective scattering from all
the particles contribute to the signal. This is in contrast to
single optical particle counting like LO. The samples were
added to the sample dispersion unit, filled with Milli-Q-
water. The sonication was turned off to avoid breaking up
large droplets. The following parameters were applied:
absorbance: 0.001 and refractive index: 1.46. The in-
struments performance was verified with polystyrene
microspheres.
Light obscuration
To investigate changes in the large diameter tail of the fat
emulsion, LO was used. The sensor was set in extinction
mode and the detection threshold was 1.80 μm. Dilution
of samples was performed in a 40 ml glass beaker with
Milli-Q-water. A micropipette was used for sampling.
Samples were diluted to concentrations below the in-
strument’s coincidence limit of 9000 particles/ml, using
dilution factors of 1:400–8000 (sample:water). The sam-
ples were stirred for 60 seconds prior to measurements
[53]. The sample withdrawal from the diluted emulsions
was 15 ml. The counts were distributed over 128 channels,
and the equivalent spherical volumes of the oil droplets
were calculated. The density of oil used in calculations
was 0.92 g/ml and the final fat composition varied be-
tween 0.038 to 0.040 g/ml (including fat from Vitalipid®
Adult) depending on the respective TPN product (Table 4).
The volume weighted percentage of fat (PFAT) greater
than 2, 5 and 10 μm, were estimated to look for active
growth in different size fractions of the large diameter
tail. The calculations were done as described in the lit-
erature [33, 53].
Microscopy
The emulsion droplets were studied in a light microscope
(LM) under 1000 × magnification (Zeiss Axioscope 451485
Light microscope, Carl Zeiss AG, Jena, Germany). A small
sample-droplet was placed upon a slide, and covered with a
slide with immersion oil. The preparation was studied and
photographed (Cannon EOS 300D Digital, Canon, Tokyo,
Japan). Due to the lack of a measuring ocular of adequate
fineness, a 5 μm scale was added to the images afterwardswith the aid of reference images of 5 μm and 10 μm poly-
styrene microsphere size standards.
pH-measurements and theoretical consideration
The pH was measured, and theoretical considerations
regarding emulsion stability were performed.
Zeta potential measurements
The zeta potential of the samples was determined by
laser doppler micro-electrophoresis (Zetasizer Nanoseries
Nano Z) (Malvern instruments, Worcestershire, UK) using
a folded capillary sample cell (DTS 1060, Malvern,
Worcestershire, UK). In this technique, the emulsion is
diluted in a medium that is exposed to an electric field,
which causes movement of the charged emulsion drop-
lets to the oppositely charged pole. At the same time
the sample is illuminated with a laser beam. The move-
ment causes a shift in the frequency of scattered light
(“Doppler shift”), which is used to determine the velocity
of the movement of the droplets, the electrophoretic mo-
bility and the zeta potential [49]. The samples were diluted
1:1000 (sample:water) in distilled water [25]. The calibra-
tion of the instrument was checked with a zeta potential
transfer standard (−68 mV ± 6.8 mV) (Malvern Instru-
ments, Worcestershire, UK).
Statistical analysis
For group comparison of the results, one-way ANOVA
followed by Tukey’s Post Hoc test was applied, α = 0.05
(Minitab® 16 Statistical Software, Minitab Inc., USA).
Student’s t-tests (SPSS) were also applied to compare
two means.
Results and discussions
Selection of test materials
Since the purpose of this study was to establish a set of
methods suitable for the detection of possible Y-site in-
compatibility of TPN and i.v. drugs, test materials were
selected for which there were existing compatibility re-
ports available in literature. Acyclovir is known to pre-
cipitate when mixed with TPN [11, 12, 24, 25]. This
drug was included as a positive control on precipitation.
Ampicillin has shown conflicting results in the literature,
some has reported formation of precipitate [24, 30]
whereas others have concluded that the drug is compat-
ible with TPN [11, 12]. Ondansetron has been reported
to destabilize the emulsion [12], although other studies
have reported no change [13, 25, 54]. There are very few
studies on paracetamol and TPN, we found only one
available report and it concluded with compatibility [13].
It should be notated noted that paracetamol is available
in different formulations in generic products, and it was
also included as a realistic example of dealing with pos-
sible effects related to generic formulation diversity.
Table 4 Composition of the three 3-in-1 TPN admixtures per liter
Olimel® N5E
TPNaq/TPN
Kabiven®
1900 kcal
TPNaq/TPN
SmofKabiven®
1600 kcal
TPNaq/TPN
Lipids total (g) -/39.2 -/38.2 -/36.9
Olive oil (%) -/80 -/- -/25
Soybean oil (%) -/20 -/100 -/30
MCT (%) -/- -/- -/30
Fish oil (%) -/- -/- -/15
Glucose anhydrous (g) 113.9/112.7 96.5/95.6 124.9/123.3
Amino acids total (g) 32.6/32.3 32.8/32.5 50.1/49.4
Alanine (g) 4.7 4.6 7.0/6.9
Arginine (g) 3.2 3.3/3.2 6.0/5.9
Aspartic acid (g) 0.9 1.0 -
Glutamic acid (g) 1.6 1.6 -
Glycine (g) 2.3/2.2 2.3/2.2 5.5/5.4
Histidine (g) 1.9 2.0 1.5
Isoleucine (g) 1.6 1.6 2.5
Leucine (g) 2.3/2.2 2.3/2.2 3.7
Lysine (g) 2.6/2.5 2.6 3.3
Methionine (g) 1.6 1.6 2.1
Phenylalanine (g) 2.3/2.2 2.3/2.2 2.5
Proline (g) 1.9 2.0 5.6/5.5
Serine (g) 1.3 1.3 3.3/3.2
Taurine (g) - - 0.5
Threonine (g) 1.6 1.6 2.2
Tryptophan (g) 0.5 0.5 1.0
Tyrosine (g) 0.1 0.1 0.2
Valine (g) 2.1 2.1 3.1/3.0
Sodium (mmol) 34.6/34.3 30.8/30.6 40.1/39.5
Potassium (mmol) 29.7/29.4 23.2/22.9 30.1/29.6
Magnesium (mmol) 4/3.9 3.9/3.8 5.0/4.9
Calciuma (mmol) 3.5/3.4 1.9/1.9 2.5/2.5
Phosphateb (mmol) 11.9/14.9 6.8/9.7 9.9/12.7
Acetate (mmol) 36.1/35.8 37.6/37.3 104.9/103.5
Chloride (mmol) 44.6/44.1 44.9/44.4 34.7/34.3
Zink (mmol) - - 0.04
Sulphate (mmol) - 3.6/3.8 5.0/4.9
α tocoferol - - n.s
Phospholipids from egg n.s n.s n.s
Glycerol n.s n.s n.s
Sodium oleate n.s - n.s
Water for injections n.s n.s n.s
pH 6.4 5.6 5.6
Table 4 Composition of the three 3-in-1 TPN admixtures per liter
(Continued)
Tracel®c (ml) 10/9.9 9.7/9.6 13.5/13.4
Soluvit®c (vials) -/1 -/1 -/1.3
Vitalipid® adultc (ml) -/9.9 -/9.6 -/13.4
a: calcium chloride as calcium source
b: from sodium glycerophosphate, the emulsion and Vitalipid® adult
c: additives
Excipients other than for pH adjustment are listed
n.s. the quantity is not stated
Source: SmPC from the respective TPN products
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(Table 4). The amino acid content of Olimel® N5E and
Kabiven® was similar, whereas the content of SmofKabi-
ven® was higher and of different composition. Olimel® N5E
had the highest content of calcium and phosphate, and
Kabiven® the lowest. According to the manufacturers’
specifications, all three TPN products could tolerate more
electrolytes, meaning that they were not stressed to their
maximum. The pH was 0.8 pH units lower in Kabiven®
and SmofKabiven® as compared to Olimel® N5E (Table 4).
Altogether, the selected products represented some vari-
ability in TPN admixture composition.
Assessment of potential precipitate
Methods suitable to assess precipitates should be able to
detect visual and sub-visual particles if present, and to
estimate their particle size and number. In order to give
the correct result, the appropriate sample preparation
method is foremost important. Samples prepared by the
centrifugation method showed that it was difficult to re-
move all traces of lipids and emulsifiers from the aque-
ous phase, resulting in samples with an inherent Tyndall
effect (see Fig. 1). This was causing problems for further
assessment of precipitation for all methods. An older
report suggests diluting the remaining aqueous-phaseFig. 1 Illumination with a Tyndall beam of samples prepared by
different strategies. Left: approach I) centrifugation of 3-in-1 TPN
and removal of supernatant, Right: approach II) lipid compartment
replaced with Milli-Q water (TPNaq). The centrifuged sample had a
turbidity reading of 117 FNU and TPNaq 0.08 FNU
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centrifugation) with water to ease the visual examination
of particles (presumably by diluting the cloudiness caused
by the remnants of the oil phase) [12]; however this might
result in re-dissolving precipitated particles and should be
avoided. Another concern may be that microprecipitate
adhere to the fat droplets, and therefore will be removed
together with the lipids and remain undetected with
this set-up.
The sample preparation where the lipid compartment
was replaced by Milli-Q water (TPNaq) gave a clear solution
with very low Tyndall effect (Fig. 1). The disadvantage of
this approach might be that since the lipid compartment
and vitamins are omitted the potential impact of them on
the precipitation will not be captured. In the case of poorly
water-soluble drugs the lipid compartment might contrib-
ute to keeping the drug in solution [55], and removing the
solubilizing aid would result in precipitation. This would
give a false positive result, which in compatibility evaluation
is less serious than the opposite. Adding lipid emulsion
might increase the pH of TPN, since pure emulsion has pH
values between 6.0 and 9.0 [43], therefore it is important to
know the pH in both the TPNaq and TPN. However, the
buffer capacity of the amino acids will likely prevent a large
difference [7, 9]. Mirtallo listed drugs showing different
compatibility in 2-in-1 versus 3-in-1 TPN mixtures [55] but
the discrepancies were mostly due to emulsion disruption
and not precipitation [56]. When it comes to the vitamins,
it has been reported that Vitamin C might degrade to oxalic
acid and precipitate with calcium [9, 10]. Nevertheless, only
one report of drug forming precipitate in Y-site with multi-
vitamins (pantoprazole sodium) was identified in the Hand-
book on injectable drugs [56], although a scarcity of studies
can contribute to the lack of reports. Finally, similar sample
preparation approaches have been suggested earlier in other
compatibility studies of TPN and drugs [13, 26]. The results
from the assessment of precipitation with different methods
are summarized in Table 5.
Visual examination using Tyndall light
Only samples containing acyclovir showed clear signs of
precipitation visually. Immediately after mixing with TPNaq
small needle shaped particles could be seen using Tyndall
light. After four hours the precipitation was obvious also
for the unaided eye in normal light (Table 5). For ampicillin
the precipitation was not clearly detected by visual examin-
ation because this drug also displayed a Tyndall effect alone.
Also one of the paracetamol formulations showed this
property (Table 3 and Table 5). The observations of Tyndall
effect in the original drug solutions made it difficult to per-
ceive possible additional particles or haze due to incompati-
bility. This has been discussed in more detail in a study on
the validity and reliability of visual examination with
Tyndall light for compatibility testing [48].Light obscuration
As expected, low total particle counts were detected in
pure TPNaq, i.e. close to the background of the tubes
(Table 5). An increasing, although varying, number of
particles (≥0.5 μm/ml) were detected in samples of
TPNaq as they were titrated with 0.1 M NaOH to force
precipitation (Fig. 2a). Once alkali was added the mean
particle count increased markedly to over 1000 counts
per ml. Increasing the pH above the pKa2 of phosphoric
acid at 7.2 [57], a jump in the particle content could be
observed. Following acyclovir + TPNaq every 30 min,
from immediately after mixing up to four hours, the par-
ticle counts increased continuously, although the variation
was large. Immediately after mixing, the particle content
was already increased to almost 1000 particles/ml.
The particle counts indicated a massive growth in
number of particles for both acyclovir and ampicillin
after mixing with all TPNaq (Table 5). Immediately after
mixing the detected particle numbers showed high vari-
ability, but there was a strong increase within the four
hours of the study (Table 5 and Fig. 2b). As mentioned
above, whether ampicillin is compatible or not with TPN
is disputed in literature. However, in the current study a
clear indication of precipitation taking place was found
for all three TPNaq solutions investigated: The highest
amount of particles was found in Olimel® N5E, which
might be an effect of pH (TPN with the highest pH be-
fore the addition of drug with alkali pH) or caused by
the higher content of calcium and phosphate (Table 4).
LO seemed to be a sensitive method for detecting on-
going precipitation.
Some factors can affect the results: Micro-bubbles may
be counted as particles [58], particles adhering to con-
tainer surfaces might not be counted [9, 11, 14], and some
types of particles might be undercounted or others give
too high counts, causing artifacts [59]. Therefore, some
caution and experience in interpreting LO results are ne-
cessary. The smallest particles (<2 μm) are counted less
accurately [58]. We do have experience with precipitation
in other samples not part of this study, that was detected
by visual examination and turbidimeter and not by LO,
possibly because the particles were smaller than the detec-
tion limit of LO instrument. Due to their numerous
amounts and collective light scattering, they could be seen
in Tyndall light and by turbidity measurements. Further-
more, large particles present in low numbers might not be
detected by LO [59], and other methods, such as visual ex-
aminations, might be more appropriate. Conversely: there
are situations where LO counts many particles without
these being detected with turbidimetri or Tyndall light. It
clearly depends on the type of particles and other influen-
cing factors. The main advantages of LO is that it is rapid
and provides numerical and objective counts of particles
as compared to visual methods [31, 48, 57].
Table 5 Results from assessment of precipitation in TPNaq
TPNaq Drug Time after
mixing h
Light obscuration Visible particles
and/or Tyndall
effect (+/−)
Turbidity (FNU) pH
Particles Particles Particles Particles
≥0.5 μm/ml ≥5 μm/ml ≥10 μm/ml ≥25 μm/ml
None Acyclovir alone - 238 ± 58 3 ± 1 1 ± 0 0 ± 0 - 0.07 ± 0.00 10.03
Ampicillin alone - 144 ± 50 1 ± 1 0 ± 0 0 ± 0 c+ 0.94 ± 0.06 8.87
Ondansetron alone - n.d. n.d. n.d. n.d. - 0.08 ± 0.01 4.21
Paracetamol alonea - n.d. n.d. n.d. n.d. c+ 0.59 ± 0.01 5.33
Paracetamol aloneb - n.d. n.d. n.d. n.d. - 0.08 ± 0.00 5.42
Olimel® N5E Fresh without drug - 119 ± 63 2 ± 2 1 ± 1 0 ± 1 d+ 0.10 ± 0.03 6.30
Acyclovir 0 810 ± 190 37 ± 17 6 ± 3 0 ± 0 ++ 0.38 ± 0.37 7.80
4 6763 ± 1148 4051 ± 1578 2513 ± 1470 691 ± 679 +++ 138.09 ± 211.14 7.63
Ampicillin 0 485 ± 412 4 ± 2 1 ± 0 0 ± 0 e+ 0.43 ± 0.12 7.93
4 9550 ± 2285 1 ± 1 0 ± 0 0 ± 0 e+ 0.49 ± 0.18 7.81
Ondansetron 0 246 ± 102 1 ± 1 0 ± 0 0 ± 0 - 0.08 ± 0.02 6.22
4 287 ± 84 2 ± 2 0 ± 0 0 ± 0 - 0.08 ± 0.01 6.15
Paracetamol 0 242 ± 104 9 ± 3 1 ± 2 0 ± 0 - 0.10 ± 0.00 6.19
4 153 ± 75 11 ± 6 2 ± 1 0 ± 0 - 0.09 ± 0.01 6.17
Kabiven® Fresh without drug - 16 ± 2 0 ± 0 0 ± 0 0 ± 0 d+ 0.13 ± 0.03 5.59
Acyclovir 0 3271 ± 2421 410 ± 361 128 ± 98 22 ± 16 ++ 2.16 ± 1.80 7.18
4 7520 ± 229 6432 ± 211 5163 ± 171 2540 ± 33 +++ 683.50 ± 135.06 7.10
Ampicillin 0 157 ± 101 2 ± 1 1 ± 1 0 ± 0 e+ 0.61 ± 0.22 7.77
4 3851 ± 2300 2 ± 1 1 ± 1 0 ± 0 e+ 0.64 ± 0.18 7.67
Ondansetron 0 103 ± 57 5 ± 1 2 ± 1 0 ± 0 - 0.11 ± 0.01 5.55
4 88 ± 2 2 ± 2 1 ± 2 0 ± 0 - 0.12 ± 0.02 5.55
Paracetamol 0 128 ± 125 1 ± 0 0 ± 0 0 ± 0 - 0.10 ± 0.02 5.56
4 36 ± 23 0 ± 0 0 ± 0 0 ± 0 - 0.10 ± 0.01 5.56
SmofKabiven® Fresh without drug - 171 ± 100 5 ± 5 3 ± 3 1 ± 1 d+ 0.11 ± 0.03 5.50
Acyclovir 0 650 ± 278 23 ± 8 4 ± 1 0 ± 0 ++ 0.11 ± 0.02 6.48
4 7088 ± 456 4043 ± 745 2177 ± 697 290 ± 139 +++ 86.83 ± 36.60 6.47
Ampicillin 0 505 ± 185 7 ± 6 2 ± 2 0 ± 0 e+ 0.26 ± 0.04 7.64
4 2531 ± 1196 3 ± 2 1 ± 1 0 ± 0 e+ 0.27 ± 0.04 7.48
Ondansetron 0 172 ± 73 1 ± 1 0 ± 0 0 ± 0 - 0.09 ± 0.01 5.47
4 231 ± 110 1 ± 0 1 ± 0 0 ± 0 - 0.09 ± 0.01 5.49
Paracetamol 0 325 ± 73 2 ± 0 1 ± 0 0 ± 0 f+ 0.32 ± 0.01 5.38
4 341 ± 182 1 ± 0 1 ± 0 0 ± 0 f+ 0.33 ± 0.01 5.38
a: B. Braun; b: formulations other than B. Braun’s; c: Tyndall effect in pure drug solution, no particles; d: very weak Tyndall effect in pure TPNaq solution, no
particles; e: might be a combination of Tyndall effect in pure drug solution and very fine particles; f: probably due to Tyndall effect in pure drug solution and
not precipitation
Mean ± standard deviation (n = ≥ 3)
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Increased turbidity (FNU) was detected in samples of
TPNaq with forced precipitation (Fig. 2c), approaching
0.2-0.3 FNU after the initial adding of alkali. Ap-
proaching pH 7.2, the turbidity was around 4 FNU. The
turbidity increased over time in mixtures of acyclovir
and TPNaq (Fig. 2d), however, the measured turbidity
showed increasing variation due to varying degree ofsedimentation of the larger and more heavy particles.
Immediately the turbidity was 0.38 FNU increasing to
0.44 after 30 min.
As shown in Fig. 3a both the spectrophotometer and
the turbidimeter gave a linear response measuring the
increasingly turbid formazin standards. Nevertheless,
looking closer at samples of low turbidity (<1 FNU) the
measured relative transmittance (T/T0) showed more
Fig. 2 Results from light obscuration (a-b) and turbidimetric measurements (c-d) on two different precipitation reactions. a increasing number of
particles larger than 0.5 μm per ml as the pH of TPNaq increases from addition of 0.1 M NaOH (n > 3). The first column represents TPNaq without
added NaOH; b particles larger than 0.5 μm per ml in samples of TPNaq and Acyclovir (1 + 1) at different time points after mixing (n = 3); c increasing
turbidity with increasing pH of TPNaq (n = 2). The first column represents TPNaq without added NaOH; d turbidity in samples with TPNaq and Acyclovir
(1 + 1) at different time points after mixing (n = 3)
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Spectrophotometers are not recommended for samples
with very low turbidity, but are more suitable at higher
turbidity values (optimal range 20–1000 units) [51]. As
it has been suggested to define incompatibility as a
change in turbidity of 0.50 NTU [29], a turbidimeter
should be preferred in order to detect such small differ-
ences. [FNU is equivalent to NTU up to 40 NTU [52]].
The mixed samples containing ampicillin showed higher
turbidity values than the rest of the samples, indicating the
presence of a precipitation (Table 5). However, ampicillin
alone had an even higher value. Ampicillin is a powder be-
fore reconstitution; therefore it might be speculated that
undissolved drug particles were causing this. However, the
drugs were filtered 0.22 μm before mixing, reducing this,Fig. 3 Turbidity measurements by two methods. a Turbidity of formazin stan
UV–vis spectrophotometer (relative transmittance in green) T0 =Milli-Q-water
of samples of drug: TPNaq (1 + 1) and pure drug solutions. T0 = TPNaq (n=≥3)and LO measurement of pure drug solution did not show
particle growth over time (data not shown). The Tyndall
effect observed could be due to fluorescence of the
drug [48, 60] or that ampicillin form micelles in aque-
ous solution [61]. When in doubt, comparing samples
to controls of drug diluted in Milli-Q-water might be
useful for drugs with inherent turbidity. Fox et al. com-
pared samples to TPN:sterile water and drug:sterile water
(ratio 1 + 1) controls in a compatibility study [26]. The tur-
bidity of samples with paracetamol and ondansetron
remained low after mixing with TPNaq except for mixtures
with TPNaq from SmofKabiven®. The latter seems to be at-
tributed to the paracetamol formulation (inherent Tyndall
effect) rather than a result of mixing with SmofKabiven®.
Since the tests were performed over an elevated period ofdards (3, 6, 18 and 30 NTU) measured with turbidimeter (FNU in pink) and
(n= 3). b Relationship between measured relative transmittance and FNU
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pending on what was available from the local hospital
pharmacy, but only paracetamol varied in excipient
composition (Table 3). The formulation from B. Braun
showed high turbidity values, which might be caused
by hydroxyethyl starch forming a colloidal suspension.
The turbidity method and the visual examination captured
the difference in formulation between these drug products.
pH measurement and theoretical consideration
Since most drugs are weak acids or bases, their solubility
will be pH-dependent. The final pH in a mix of TPN
and drug will depend on the pH of the formulations,
buffering capacity and the concentrations. TPN products
possess a large buffer capacity, because of the content of
amino acids and acetate and can often withstand large
changes in pH [7, 9].
In the current study, acyclovir and ampicillin stands
out with quite alkaline pH values (Table 5), which in-
crease the risk of calcium phosphate precipitation [57],
or precipitation of the unionized drug upon mixing with
the less alkaline TPNaq. Acyclovir is sparingly to slightly
soluble in water, whereas the sodium salt is soluble 1 in
10 of water [62]. The pKa value of the proton donating
group is 9.3 [63]. After mixing with TPNaq the pH value
is too low for the drug to be sufficiently ionized, and at
the same time high enough to cause calcium phosphate
precipitation. Hence, the observed precipitation can be a
result of both.
Ampicillin is an ampholyte with pKa of 2.5 (−COOH
group) and 7.3 (−NH2 group) [62], and shows the lowest
solubility at the isoelectric pH: 4.9 [64]. Upon mixing
with TPNaq the pH is well above the pI, which indicates
that the observed precipitation should be from calcium
phosphate.
Ondansetron hydrochloride has a pKa value of 7.4 and
is soluble in water, but the solubility decrease when pH
is > 5.7 [62]. Precipitates can form at pH 5.7 and 7, but it
has been reported that the precipitate can be re-dissolved
at pH 6.2 [56]. The pH of commercially available
ondansetron solutions are adjusted with acidic buffer to
be in the range of 3.3 to 4 [56]. The measured pH values
of Kabiven® and SmofKabiven® mixed with ondansetron
were below 5.7 and the pH value of Olimel® N5E was
around 6.2. These findings support the fact that no signs
of precipitation were observed with ondansetron in the
current study.
A situation where the prediction of compatibility is
not straightforward can be illustrated with paracetamol.
Paracetamol’s phenol group has a pKa of 9.7 [63], which
mean it is a neutral molecule below this pH. The formu-
lations’ pH-values are on the acidic side (pH 4.5 up to
5.5-7.0 (Table 3)), which after mixing with TPNaq was
found to approach the pH of the respective TPNproducts. Paracetamol is very slightly soluble in cold
water [62]. A typical formulation of paracetamol has a
concentration of 10 mg/ml, and the presence of mannitol
(Table 3) probably acts as a co-solvent. Therefore, two sce-
narios might be relevant when mixing with TPN in Y-site;
1) the solubility of paracetamol is aided through dilution
into a larger volume or 2) the concomitant dilution of
mannitol might decrease the solubility leading to precipi-
tation of paracetamol. It is difficult to predict the outcome
on a theoretical level. Other excipients in the paracetamol
formulations might also affect Y-site compatibility, and in
the current study three generic drugs of paracetamol were
investigated. Excipients are stated in the manufacturers
SmPC, but not quantitatively (Table 3). Two of the formu-
lations contained cysteine, which might precipitate with
copper [9]. This might be a problem when mixing these
formulations with TPN containing a lot of trace elements.
One of the formulations contained disodium phosphate
dihydrate. This might increase the risk of calcium
phosphate precipitation, especially if mixed with a TPN
product already added maximum electrolytes. To better
predict compatibility it would be helpful to know the
exact amount of excipients in the formulations. Further-
more, one of the formulations contained hydroxyethyl
starch. Some etherified starches (hetastarch) are incompat-
ible with many compounds [65], and might be a factor to
take into consideration.
Theoretical considerations of the drugs’ pKa value (s),
functional groups, solubility and excipients, together with
pH-measurements are important tools in predicting com-
patibility [64], and should always be an essential part in
compatibility assessments. Because theoretical evaluations
are not necessarily straightforward, a combination of
theory and experiments is advisable.
Emulsion stability analysis
Methods suitable to assess the emulsion stability upon
mixing TPN with drugs should be able to detect changes
in the droplet size. Early signs of destabilization can be
recognized as an increase in the number of large diameter
droplets, and at a later stage a shift of the droplet size
distribution towards larger droplets. The results from
the emulsion stability analysis can be seen in Table 6.
Dynamic light scattering
All TPN products tested showed I.W. MDD well below
500 nm and comply with the USP requirements; Kabi-
ven® had the largest I.W. MDD with 287 ± 11 nm and
SmofKabiven® the smallest with 248 ± 1 nm (Table 6).
Based on the DLS results, the MDD of Olimel® N5E did
not change during heat destabilization, but for Kabiven®
and SmofKabiven® it increased slightly after four days of
heating, but were still well below 500 nm. Only minor
changes were detected in MDD after mixing with drugs
Table 6 Results on emulsion stability
TPN Drug Time
after
mixing
h
Laser diffraction Dynamic light scattering Light obscuration ζ (mV) pHd
a% < 500 nmb a% < 1 μmc a% > 5 μmc a% > 10 μmb V.W. MDD nm I.W. MDD nm PI PFAT2 PFAT5 PFAT10
Olimel® N5E Fresh without drug - 91 100 0 0 330 ± 0 273 ± 2 0.05 ± 0.03 0.04 ± 0.01 0.02 ± 0.01 0.01 ± 0.01 −38 ± 3 6.38
Heated 2 days (45 °C) - 89 100 0 0 344 ± 2 266 ± 2 0.06 ± 0.01 5.43 ± 0.24 4.47 ± 0.22 1.17 ± 0.08 −38 ± 1 6.27
Heated 4 days (45 °C) - 68 75 9 5 1531 ± 25 275 ± 2 0.09 ± 0.03 5.60 ± 2.60 4.55 ± 2.26 2.19 ± 1.26 −41 ± 4 6.17
Ampicillin 0 91 100 0 0 326 ± 1 272 ± 3 0.05 ± 0.02 0.05 ± 0.02 0.03 ± 0.02 0.02 ± 0.02 −51 ± 1 7.95
4 92 100 0 0 326 ± 15 270 ± 1 0.05 ± 0.02 0.04 ± 0.02 0.02 ± 0.02 0.02 ± 0.02 −53 ± 2 7.83
Ondansetron 0 90 100 0 0 325 ± 1 273 ± 2 0.06 ± 0.02 0.05 ± 0.00 0.03 ± 0.00 0.01 ± 0.01 −35 ± 2 6.17
4 91 100 0 0 322 ± 0 272 ± 3 0.06 ± 0.02 0.04 ± 0.00 0.02 ± 0.01 0.01 ± 0.01 −41 ± 1 6.16
Paracetamol 0 90 100 0 0 322 ± 0 274 ± 2 0.09 ± 0.01 0.04 ± 0.00 0.02 ± 0.00 0.01 ± 0.00 −43 ± 2 6.21
4 91 100 0 0 318 ± 0 274 ± 7 0.06 ± 0.01 0.04 ± 0.01 0.02 ± 0.01 0.01 ± 0.00 −38 ± 2 6.20
Kabiven® Fresh without drug - 82 100 0 0 365 ± 0 287 ± 11 0.11 ± 0.04 0.22 ± 0.04 0.12 ± 0.03 0.05 ± 0.03 −37 ± 2 5.55
Heated 2 days (45 °C) - 76 100 0 0 393 ± 0 287 ± 2 0.10 ± 0.01 6.35 ± 1.25 5.06 ± 1.04 1.65 ± 0.32 −39 ± 2 5.40
Heated 4 days (45 °C) - 66 81 9 5 1616 ± 27 316 ± 19 0.25 ± 0.10 6.67 ± 0.22 5.48 ± 0.42 3.01 ± 0.89 −38 ± 3 5.48
Ampicillin 0 83 100 0 0 353 ± 0 275 ± 2 0.07 ± 0.03 0.12 ± 0.01 0.06 ± 0.01 0.02 ± 0.01 −51 ± 1 7.92
4 83 100 0 0 359 ± 0 278 ± 1 0.09 ± 0.01 0.10 ± 0.02 0.06 ± 0.02 0.04 ± 0.02 −51 ± 3 7.82
Ondansetron 0 83 100 0 0 355 ± 0 280 ± 2 0.07 ± 0.01 0.11 ± 0.01 0.06 ± 0.01 0.02 ± 0.00 −37 ± 1 5.55
4 84 100 0 0 346 ± 0 280 ± 2 0.09 ± 0.02 0.13 ± 0.00 0.06 ± 0.00 0.02 ± 0.00 −37 ± 1 5.55
Paracetamol 0 82 100 0 0 364 ± 0 277 ± 1 0.09 ± 0.02 0.11 ± 0.00 0.05 ± 0.00 0.02 ± 0.00 −38 ± 2 5.63
4 83 100 0 0 357 ± 0 281 ± 2 0.07 ± 0.00 0.13 ± 0.00 0.07 ± 0.02 0.03 ± 0.01 −40 ± 2 5.60
SmofKabiven® Fresh without drug - 89 100 0 0 326 ± 0 248 ± 1 0.06 ± 0.01 0.31 ± 0.13 0.22 ± 0.11 0.06 ± 0.04 −34 ± 2 5.43
Heated 2 days (45 °C) - 66 84 5 2 980 ± 11 279 ± 4 0.15 ± 0.03 5.65 ± 1.07 4.51 ± 1.01 1.79 ± 0.81 −33 ± 3 5.39
Heated 4 days (45 °C) - 22 41 30 14 4083 ± 75 342 ± 10 0.29 ± 0.03 8.69 ± 0.97 6.97 ± 0.84 3.21 ± 0.45 −38 ± 3 5.36
Ampicillin 0 89 100 0 0 324 ± 0 242 ± 2 0.08 ± 0.02 0.35 ± 0.25 0.27 ± 0.22 0.10 ± 0.10 −48 ± 2 7.52
4 90 100 0 0 317 ± 0 242 ± 1 0.08 ± 0.01 0.22 ± 0.10 0.14 ± 0.08 0.04 ± 0.02 −49 ± 2 7.34
Ondansetron 0 89 100 0 0 324 ± 0 249 ± 1 0.08 ± 0.01 0.37 ± 0.16 0.27 ± 0.14 0.08 ± 0.05 −37 ± 2 5.54
4 89 100 0 0 330 ± 1 247 ± 1 0.08 ± 0.02 0.57 ± 0.08 0.39 ± 0.07 0.11 ± 0.05 −34 ± 1 5.56
Paracetamol 0 89 100 0 0 324 ± 0 242 ± 2 0.08 ± 0.02 0.38 ± 0.27 0.28 ± 0.25 0.12 ± 0.13 −39 ± 2 5.34
4 90 100 0 0 325 ± 1 244 ± 7 0.11 ± 0.04 0.83 ± 0.58 0.44 ± 0.22 0.12 ± 0.08 −40 ± 4 5.34
a: volume weighted % of oil droplets; b: standard deviation 0–2 c: standard deviation 0–1; d: standard deviation 0.00-0.06
V.W. MDD volume weighted mean droplet diameter, I.W. intensity weighted, PI, polydispersity index, Mean ± standard deviation: n = ≥ 3, dynamic light scattering, n = 2 with multiple runs, laser diffraction, n = 1 with
multiple runs
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Fig. 4 Response of the light obscuration instrument to TPN without
(orange) and spiked with polystyrene size standards of 5 μm (green)
and 5 + 10 μm (purple) respectively
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the heat destabilized samples were not properly recog-
nized, it strongly suggests that DLS is not suitable for
assessing emulsion stability of TPN. The changes in
MDD as result of an increase in large diameter droplets
were too small to provide reliable data.
PI provides information to the broadness of the droplet
size distribution; a PI above 0.50 indicates a very broad size
distribution whereas values around 0.10 suggest a relatively
monodisperse distribution [66]. A broadening of the drop-
let size distribution could reflect increased droplet sizes in
the large diameter tail of the emulsion, but the PIs mea-
sured in the current study were below or around 0.10, only
heat destabilized Kabiven® (four days) and SmofKabiven®
(two and four days) showed slightly higher PIs. This
suggests that also not PI is a suitable measure for the
early signs of destabilization of TPN emulsions.
DLS is most suitable for detection of small droplets, in
the nanometer size-range, and less accurate for droplets
with diameters above 1 μm, which are the most interest-
ing for stability assessment of the TPN products. This
makes the recorded MDD and PI less suitable for stabil-
ity assessment of TPN emulsions. DLS should therefore
not be the method of choice for compatibility testing.
Laser diffraction
LD has a wider measuring range and should therefore be
better suited for the detection of the larger diameter
droplets. The V.W. MDD of all TPN products showed a
significant increase in droplet size after four days of
heating (Table 6), and all were above 500 nm. The MDD
had also increased after two days, but this was less pro-
nounced for Olimel® N5E and Kabiven®, and was probably
in range of the normal variation: e.g. for Olimel® N5E the
MDD had increased from 330 to 344 nm, an increase of
4 % after two days of heating. No increase in MDD was
detected after mixing with the drugs, and all were below
500 nm. Scrutinizing the different size fractions one could
see a tendency towards a decrease in the percent of drop-
lets below 500 nm after two days of heating for all TPN
products. An increase in number of droplets above 5 μm
was observed in the four day samples for all TPN prod-
ucts. The most pronounced changes were observed in
SmofKabiven® after four days of heating; both the decrease
in droplets below 500 nm and the increase in droplets
above 5 and 10 μm. This suggests that the method could
offer some support in the detection of destabilization.
However, LD does not appear to be a very sensitive
method since large diameter droplets were only detected
in the most destabilized samples. Also, no droplets above
1 μm were detected in any of the mixed drug: TPN sam-
ples. This seems unlikely since some droplets are normally
present in the large diameter tail, even in stable emulsions.
The limitations of ensemble techniques such as DLS andLD in detecting growth in the population of large oil
droplets have been discussed by several researchers
[42, 47, 53, 67, 68]. Nevertheless, LD ranked the stable
and destabilized emulsions in the expected order, and
the method might offer some support in finding at least
the most destabilized samples.
Light obscuration
Significant increases in PFAT values were observed after
heat-destabilization of TPN samples, both after two and
four days. The difference between two and four days was
not significant due to large variation, but the mean
values placed the samples in the correct order of stability
(larger mean in four day samples), indicating continuous
droplet growth under the stressful conditions. LO has
previously been proved superior to LD in detecting un-
stable emulsions and emulsions spiked with latex parti-
cles [42, 47]. As a control a similar test as described by
Driscoll et al. [47] was performed; TPN samples spiked
with 5 and/or 10 μm polystyrene size standards, which
turned out not to be detectable by LD (data not shown),
was detected by LO (Fig. 4). This confirmed that LO is
more sensitive for detecting large diameter droplets and
early signs of emulsion destabilization.
A drawback of LO, and several other particle sizing
methods (also DLS and LD), is the extensive dilution
necessary to avoid coincidence of multiple particles, and
this might influence the emulsion characteristics [8]. Fur-
thermore, some of the PFAT values in the current study
showed rather large variation, as can be seen in the large
standard deviations. This might be attributed to low sam-
pling volume, and an automatic dilution system [46] would
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contribute to reduce the variation between replicates.
All three TPN products showed PFAT5 values below
0.40 % before addition of drug. SmofKabiven® had the
highest PFAT5 followed by Kabiven® and Olimel® N5E.
Many factors affect the stability of these multi component
systems, like packaging, manufacturing process and raw
materials in addition to the composition [8, 44, 45, 69].
PFAT5 of Kabiven® and Olimel® N5E remained low after
mixing with drugs, whereas for SmofKabiven® PFAT values
were generally higher, and PFAT5 were sometimes found to
be above 0.40 %. The PFAT5 values of paracetamol: Smof-
Kabiven® and ondansetron: SmofKabiven® were significantly
higher after 4 h compared to pure SmofKabiven®.
A difference in PFAT of heat destabilized TPN was
detected depending on container material (data not
shown). Higher PFAT-values were found for samples
stored in glass than the same samples stores in plastic.
This has also been discussed in the literature; large oil
droplets might adhere or be absorbed to plastic con-
tainers over time [70]. Gonyon and colleagues found an
approximately 20 % decrease in PFAT5 for TPN emul-
sions stored for 6 h (ambient temperature) in plastic,
compared to almost 0 % loss when stored in glass [70].
Since plastic sample tubes were used in the current
study, a conservative approach might be to add 20 %
on the PFAT5 numbers as a precaution. Doing this, the
conclusions do not change. Glass might be a more appro-
priate material for testing the emulsion stability, although
choosing plastic might better simulate the infusion envir-
onment; plastic is often the material of infusion containers
and certainly infusion tubing.
Microscopy
As expected, the majority of the droplets were very
small, and too small to be properly identified using a
conventional LM method. Therefore the determination
of the MDD was not possible. Only larger droplets
(>1 μm) could be counted. Due to the many layers of
droplets and the droplet flattening during sample prepar-
ation, it was challenging to obtain the proper adjustment
of the focus, and to interpret the images. The number of
droplets above 2 μm and 5 μm were compared in pure,
non-treated and destabilized TPN samples (n = 5 images
per sample). This provided the appropriate ranking of
stable and heat destabilized samples, but the number of
large droplets counted varied a lot between the different
pictures (data not shown). Also the drug: TPN samples
showed large variation in the number of large droplets,
and it was difficult to draw any conclusions based on this
assessment (data not shown).
Several factors might improve the outcome of micros-
copy, such as larger sampling volumes, use of proper
contrasting technique, use of image analysis programsand more training. LM has been extensively used to in-
vestigate stability of parenteral emulsions [13, 28, 36, 37,
40], and was found to be most sensitive in detecting
large oil droplets compared to LD, DLS and coulter
counter by Müller and Heinemann [36]. It is further em-
phasized that presence of flocculation can be seen by
microscopy [8], and thus allow the distinction between
flocs and coalesced droplets. It might also be a more
readily available technique in e.g. a hospital pharmacy
setting [28, 36, 59]. Nevertheless, in our experience it re-
quires extensive training and experience to ensure the
quality and usefulness of microscopy data. It is also
time-consuming and laborious, because of the number
of samplings necessary and due to the counting process.
Driscoll et al. found a modest degree of correlation be-
tween LM and LO, and suggests microscopy only as a
support to LO [40]. Only a few droplets per field are in
focus and counted, therefore analysis and statistical depic-
tion of polydisperse samples is very difficult [49]. Problems
of obtaining representative sampling as well as statistics
are further discussed in literature [28, 40, 49].
pH-measurements and theoretical consideration
Olimel® N5E measured the highest pH value of the TPN
products followed by Kabiven® and SmofKabiven®. It ap-
peared to be a reasonable correlation between the pH of
the TPN products and their respective PFAT5 values;
the lower the pH the higher PFAT5. Evaluation of pH
and other factors (ionic strength, dilution etc.) might
help to understand and predict emulsion instability upon
mixing with drugs, however, droplet size measurements
should be performed.
Similar to the TPNaq measurements, the pH values did
not change much after addition of drugs, with the excep-
tion of ampicillin. There were some small differences
between pH values measured in drug: TPN and drug:
TPNaq, mean differences of 0.01-0.15 units (Table 5
and 6). However, these small differences seem less im-
portant and should not imply a notable different risk of
precipitation in TPN versus TPNaq.
Zeta potential measurements
It is known that the pure lipid injectable emulsion typic-
ally has a zeta potential of–30 to–50 mV, due to the
negatively charged phospholipids [8]. This charge causes
a mutual repulsion between emulsion droplets, keeping
them separated and stabilizing the emulsion. At zero po-
tential there is a great risk of emulsion cracking. Because
of the presence of many positively charged ions, the zeta
potential in TPN is much smaller than in pure lipid
emulsion [8, 34, 71]. Different dilution media are reported
in the literature for measuring zeta potential of TPN; some
dilute in distilled water [25, 28, 38], while others compose
an identical TPN aqueous-phase without the lipids and
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in the composed TPN water-phase would give zeta poten-
tials around−/+ 1–2 mV, and these small potentials are in
the same order of magnitude as the accuracy of the instru-
ment [8], it may be difficulty to elicit effects on the zeta
potential of TPN. Sample heating can also be a problem.
Therefore, dilution with water was chosen in the current
study, although this means comparing relative differences
and not the true values.
The zeta potential of drug: TPN mixtures is a result of
several factors. Cations (e.g. Ca2+, Na+, K+ and H+) pull
the zeta potential closer to zero by non-specific and spe-
cific adsorption to the droplet surface [8, 71]. Therefore,
drugs diluted in NaCl might be more likely to affect the
zeta potential, than drugs diluted in glucose. Glucose, al-
though acidic, is not expected to have a large effect on
the zeta potential of TPN because of the buffering effect
of the amino acids [8, 34]. All the drugs, except ampicil-
lin, were mixed in 5 % glucose. The zeta potential might
also be affected by the pH of the drug solution or the
drug molecule itself.
Generally, the zeta potentials of the tested drug: TPN
combinations were in the range –30 to –40 mV, only
ampicillin was standing out with a zeta potential around
–50 mV with all TPN products. The alkaline pH of
ampicillin (pH 8.87), can explain the more negative po-
tential. None of the other drugs seemed to greatly affect
the zeta potential, even though deviations from the
original samples were recorded. The minimal changes in
pH after mixing with drug support this finding.
Diluting in water does not provide the real potential
and thus no information on how close to zero the poten-
tial really is, as pointed out above. It was therefore diffi-
cult to assess emulsion stability from this and therefore
zeta potential measurements alone are not suitable for
compatibility assessments. However, it might support
the understanding of what is going on in the mixtures–
at least the direction of the charge, but this information
could also be inferred from the pH-measurements.
Discussion of test program and compatibility testing
All the characterization methods used in the current
study have their strengths and weaknesses. Investigating
compatibility of drugs and complex systems, such as
TPN admixtures, requires testing with multiple methods
and a thorough evaluation of several indicators of in-
compatibility to draw safe conclusions. The collective re-
view of result from a panel of qualified methods can
provide more robust data; therefore, the statistical tests
were limited to investigations into the separate methods
and not used for the overall compatibility evaluation.
For the assessment of potential precipitation the
total evaluation of sub-visual particle counts (LO), tur-
bidity, visual examinations using Tyndall light and pHmeasurements made it possible to indicate the presence of
precipitates. They all captured different indications of
precipitation and should be used together to increase
the chance of detecting incompatible blends.
For the analysis of emulsion stability, LO followed by
estimation of PFAT5 seemed to be the most sensitive
method, since it individually counts the droplets in the
large diameter tail [47]. It also gave the most marked
response following the droplet distribution from the
original samples to heat destabilized TPN in this study.
Furthermore, LO is the method recommended by the
USP for investigating the large diameter tail of lipid in-
jectable emulsions [41]. A drawback of LO was its low
repeatability at times. LD seemed more robust in this
sense. We suggest LD, pH measurements and theoretical
evaluation as complementing methods to LO for testing
emulsion stability. The DLS did not provide additional in-
formation on mean droplet size, and was not sensitive
enough to detect small changes in the large diameter tail.
The LM method used was sub-optimal, but with appropri-
ate adjustments and more experience this might provide
useful support. Measuring zeta potential did not add infor-
mation that could not be extracted from the pH measure-
ments, which is simpler to perform.
The compatibility data provided in the current study
are supported by scattered reports in literature, further
founding the suitability of the test program. However,
conflicting data are common, which complicates com-
parison to existing literature. Also in the current study
conflicting data was obtained, as some of the drugs were
compatible with some of the tested TPN admixtures,
but not with all. Conflicting results might occur even in
a well-controlled experiment. This emphasizes the risk
of extrapolation of results from one product to another,
and can be equally relevant for generic drug products as
for different TPN products. We believe that always using
an in-line-filter, provided the drug can be filtered, is a
useful safety measure to protect the patient during Y-site
administrations.
Discussion of acceptance criteria in compatibility testing
It is challenging to define definite numerical limits for
each of the method for what should be considered a true
incompatibility involving these complex blends. The ac-
ceptance criteria should relate to safety, and one reason
why it is challenging to define absolute criteria is that it
is not fully clear how much the body can handle of parti-
cles and enlarged oil droplets, both when it comes to sizes
and numbers, and therefore it is unclear what the methods
should detect at a minimum. Even though a change might
be detected it might not be a relevant change with clinical
significance. Furthermore, some of the results are difficult
to interpret. Take counting of sub-visual particles as an ex-
ample: Our experience is that for some samples the initial
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controls but after four hours they are much lower. This
could be a sign of a temporary, local precipitate forming
(because of concentrated layers), which dissolves with time
when the sample gets more homogenous. Or, it can be an
effect of aggregation of small particles into fewer large par-
ticles or crystal growth (Ostwald ripening) with the same
result. It can also be a result of bubbles or other artifacts.
This can be hard and time consuming to elucidate.
It is also difficult to find suitable standards for testing
and validation of the methods. Using e.g. polystyrene
particles provides some information, but since these par-
ticles are very different from both precipitates and oil
droplets, it might not be transferable to real samples.
Therefore, we have used samples that were expected to
be closer to real precipitations (forced calcium phos-
phate precipitations) and destabilized samples (heat
stressed) for testing of the methods. It is important to
notice that the “incompatibility” in these samples is not
always reproducible, so to use them as references to de-
termine the acceptance limit is complicated. But then
again, the nature of the incompatibility reaction may also
vary from time to time in a real setting. The timing and
extent of precipitation can differ even for identical sam-
ples investigated in the same study [31]. Several factors
that are not easily controlled can influence the question
of compatibility; e.g. the temperature, light conditions,
different batches of tested products etc.
Even though acceptance limits are difficult to define,
some measure of what is a large or a small change com-
pared to controls is important in order to interpret the
results. Based on the current experiences we suggest
some arbitrary limits for each method of the test pro-
gram: 1) Visual examination: No clear signs of particles
or increased Tyndall effect should be detected. 2) LO: It
is difficult to set a fixed limit for what is an alarming in-
crease in sub-visual particles. Particle counts above
0.5 μm approaching 1000–2000 particles/ml (provided
that both drug and TPN are filtered 0.22 μm before mix-
ing) is approximately 10–20 times the background count
of TPNaq, and should be a reason to react. It is also im-
portant to look for growth of larger particles (c.f. Ph.
Eur. limits) and to see how the particle counts develops
over time. If there is no clear increase over time, either
in number or particle size, it might be a compatible
blend. Noteworthy, in ampicillin: TPNaq (Table 5) sam-
ples, and TPNaq: NaOH, the Ph. Eur. limits were not
exceeded, even though a large increase in smaller parti-
cles (e.g. from 485/ml immediately to 9550 particles/
ml ≥ 0.5 μm after four hours for ampicillin: Olimel® N5E)
indicated precipitation. These small particles might grow
and aggregate with time and constitute a risk if infused.
This suggests that using the Ph. Eur limits only, may not
be sufficient when it comes to dynamic situations asprecipitation and compatibility studies. For the evalu-
ation of “static” particles such as dust, fibers, glass etc.
the Ph. Eur. limits are more applicable. 3) Turbidity: At-
tention should be payed to turbidity values > 0.20-0.30
FNU, although this has to be seen in comparison to the
background turbidity of both TPNaq and drug. Based on
experience with incompatible blends that did not exceed
the currently applied limit of 0.5 FNU, a lower level
might be suitable, and results from complementing
methods will be required for reliable judgment of com-
patibility. However, we have occasionally measured
Milli-Q-water as high as 0.18 FNU. Care should be taken
to avoid disturbing factors like scratches on sample cells,
bubbles etc. 4) pH: The pH values should be interpreted
in relation to the pKa value of the drug and the pH of
the TPN. If mixing moves the pH in direction of less
ionized drug, the solubility decreases. It is also alarming
if the pH approaches 7 with regard to calcium phosphate
precipitation, and if it is below 5.5. The latter is due to
phospholipids being ionized at pH values 5.5-9.0 [33]. At
pH values below this, the charge might start to neutralize,
increasing the risk of emulsion destabilization. However,
some phospholipids are not completely neutralized before
reaching pH 3.2 [8], therefore the emulsion might stand
lower pH values than 5.5. 5) PFAT5: It is difficult to define
an alarming increase based on the current data, and we
therefore lean on the PFAT5 limit of < 0.40 %. 6) LD:
MDD should be below 500 nm as is the requirement in
the USP. Like PFAT5, it is difficult to define an alarming
increase. Bouchoud et al. suggested a limit of less than
10 % change in MDD measured by DLS as evidence of
compatibility [13], which helps assuring that the MDD is
below 500 nm. In addition the size fractions should be
investigated, and there should be no increase in sizes
above 5 μm. Finally, to answer the ultimate question
whether “to mix or not to mix”, the responses from all
method have to be seen together, and combined with
theoretical considerations. More work and discussions
on methods and suitable acceptance criteria for com-
patibility testing is welcomed.
Conclusion
A test program suitable for investigating physical compati-
bility of drugs and TPN mixed at Y-site was established
and evaluated. The milk-white appearance of TPN admix-
tures prohibits the assessment of potential precipitation,
and a sample preparation method replacing the lipid phase
with Milli-Q-water was recommended for these experi-
ments. Light obscuration, turbidimetry, visual examination
using Tyndall beams, and pH-measurements were se-
lected methods for detecting signs of precipitation. To
investigate signs of emulsion destabilization, samples
containing the complete TPN admixture were used.
Among the tested methods light obscuration followed
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measurements were found to be the most adequate. It
should be emphasized that none of the methods should be
used alone. The different methods supply information of
complementary descriptors of compatibility and should be
seen together. Mixed samples should always be compared
to pure controls and the samples should be followed over
a period of time. Theoretical prediction is important to
understand and support the experimental tests. Accept-
ance criteria are difficult to define, although some critical
limits are suggested based on current experience.
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